Chronic thromboembolic pulmonary hypertension (CTEPH) is a type of pulmonary
hypertension, resulting from fibrotic transformation of pulmonary artery clots causing chronic …

Chronic thromboembolic pulmonary hypertension (CTEPH) is thought to result from
incomplete resolution of pulmonary thromboemboli that undergo organisation into fibrous …

Background Riociguat, a member of a new class of compounds (soluble guanylate cyclase
stimulators), has been shown in previous clinical studies to be beneficial in the treatment of …

Background—Chronic thromboembolic pulmonary hypertension results from incomplete
resolution of pulmonary emboli. Pulmonary endarterectomy (PEA) is potentially curative, but …

Riociguat is a soluble guanylate cyclase stimulator approved for the treatment of inoperable
and persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH). In the …

Background—Chronic thromboembolic pulmonary hypertension leads to pulmonary
hypertension and right-sided heart failure. The purpose of this study was to investigate the …

Pulmonary hypertension remained an unexplained intractable disease with poor prognosis.
In the last 2 decades, however, the diagnosis and treatment methods for this disease …

Chronic thromboembolic pulmonary hypertension (CTEPH), a rare consequence of an acute
pulmonary embolism, is a disease that is underdiagnosed, and surgical pulmonary …

Epidemiological data for chronic thromboembolic pulmonary hypertension (CTEPH) are
limited and there are conflicting reports regarding its pathogenesis. A literature review was …

Chronic thromboembolic disease is characterised by persistent pulmonary thromboembolic
occlusions without pulmonary hypertension. Early surgical treatment with pulmonary …